Zydus Pharmaceuticals (USA) Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zydus Pharmaceuticals (USA) Inc.
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.
Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Former sales and marketing exec at Taro Pharmaceuticals is latest exec charged with participating in price fixing conspiracies.
- Generic Drugs
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.